Nebula Research & Development LLC purchased a new position in Kura Oncology, Inc. (NASDAQ:KURA - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 63,866 shares of the company's stock, valued at approximately $556,000. Nebula Research & Development LLC owned approximately 0.08% of Kura Oncology as of its most recent filing with the Securities & Exchange Commission.
Other large investors also recently modified their holdings of the company. Harbor Advisors LLC acquired a new position in Kura Oncology during the 4th quarter valued at about $87,000. E Fund Management Co. Ltd. acquired a new stake in Kura Oncology in the fourth quarter worth approximately $90,000. Optimize Financial Inc acquired a new position in shares of Kura Oncology during the 4th quarter valued at $100,000. Corient Private Wealth LLC bought a new stake in shares of Kura Oncology in the 4th quarter worth $109,000. Finally, Teacher Retirement System of Texas grew its holdings in Kura Oncology by 19.9% during the fourth quarter. Teacher Retirement System of Texas now owns 13,749 shares of the company's stock worth $120,000 after acquiring an additional 2,285 shares during the period.
Analysts Set New Price Targets
Several equities analysts have recently weighed in on KURA shares. StockNews.com lowered shares of Kura Oncology from a "buy" rating to a "hold" rating in a research report on Friday. UBS Group reduced their target price on shares of Kura Oncology from $27.00 to $14.00 and set a "buy" rating for the company in a report on Thursday, March 6th. Barclays dropped their price target on Kura Oncology from $32.00 to $11.00 and set an "overweight" rating on the stock in a report on Friday. JMP Securities restated a "market outperform" rating and issued a $28.00 target price on shares of Kura Oncology in a report on Tuesday, April 29th. Finally, Scotiabank reduced their target price on Kura Oncology from $18.00 to $10.00 and set a "sector perform" rating for the company in a report on Wednesday, January 8th. Four investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, Kura Oncology has a consensus rating of "Moderate Buy" and a consensus price target of $23.89.
Check Out Our Latest Report on Kura Oncology
Kura Oncology Stock Up 1.6 %
NASDAQ:KURA traded up $0.11 on Monday, hitting $6.58. 201,962 shares of the company's stock traded hands, compared to its average volume of 1,156,175. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The company has a market cap of $531.12 million, a PE ratio of -2.79 and a beta of 0.50. The firm has a 50-day moving average price of $6.73 and a 200-day moving average price of $9.52. Kura Oncology, Inc. has a 1 year low of $5.41 and a 1 year high of $23.48.
Kura Oncology (NASDAQ:KURA - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.15). The business had revenue of $14.11 million for the quarter, compared to the consensus estimate of $39.08 million. Equities analysts anticipate that Kura Oncology, Inc. will post -2.44 EPS for the current fiscal year.
About Kura Oncology
(
Free Report)
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.
Recommended Stories
Before you consider Kura Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kura Oncology wasn't on the list.
While Kura Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
